Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs)

Human Vaccines

Volumn 4, Issue 4, 2008, Pages 280-285

  Ghebrehewet, Sam ^a   Baxter, David ^b   Falconer, Michelle ^c   Paver, Keith ^d  

^a Chester Microbiology Laboratory   (United Kingdom)

^b Greater Manchester Health Protection Unit   (United Kingdom)

^c Countess of Chester Health Park ^*  (United Kingdom)

^d Manchester Medical Microbiology Partnership   (United Kingdom)

Author keywords

Healthcare workers; Hepatitis B; Hepatitis B surface antibody litres; Hepatitis B surfaceantigen; Immunization; Intradermal; Intramuscular; Recombinant vaccine; Vaccination

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; IMMUNIZATION; MALE; OBSERVATIONAL STUDY; OCCUPATIONAL SAFETY; UNSPECIFIED SIDE EFFECT;

EID: 50849093597     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.4.5687     Document Type: Article

References (22)

1. Salisbury DM, Ramsay M, Noakes K Eds. Immunisation against infectious diseases. Published by TSO (The Stationery Office), Department of Health (DH) 2006; 161-84.
2. Halliday ML, Rankin JG, Bristow NJ, Coates RA, Corey PN, Strickler AC. A randomised double-blind clinical trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine compared with a plasma-derived vaccine. Archives of Internal Medicine 1990; 150:1195-200.
3. Kubba AK, Taylor P, Graneek B, Strobel S. Non-responders to hepatitis B vaccination: a review. Commun Dis Public Health 2003; 6:106-12.
4. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993; 270:2931-4.
5. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota healthcare workers. JAMA 1993; 270:2935-9.
6. Rosman AS, Basu P, Galvin K et al. Efficacy of high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomised clinical trial. Am J Med 1997; 103:217-22.
7. de Lalla F, Rinaldi E, Santoro D, Pravertoni G. Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. European Journal of Epidemiology 1988; 4:256-8.
8. Craven DE, Awdeh ZL, Kunches LM, et al. Non-responsiveness to hepatitis B vaccine in healthcare workers. Results of revaccination and genetic typing. Ann Intern med 1986; 105:356-60.
9. Noh AK, Poland GA, Murray JA. Hepatitis B vaccine non-response and celiac disease. Am J Gastroentrol 2003; 98:2289-92.
10. R Development Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2000; http://www.R-project.org
11. Hothorn T, Hornik K. exactRankTests: Exact Distributions for Rank and Permutation Tests. R package version 0.8-15, 2006.
12. Chen W, Gluud C. Vaccines for preventing hepatitis B in HCWs. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD000100. DOI: 10.1002/14651858. CD000100.pub3.
13. Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 1997; 314:329-33.
14. Averhoff F, Mahoney F, Coleman P, Schartz G, Hurtwitz E, Margolis H. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. American Journal of Preventive Medicine 1998; 15:1-8.
15. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002; 109:1519-26.
16. Dubois B, Bridon JM, Fayette J, et al. Dendritic cells directly modulate B cell growth and differentiation. J Leukoc Biol 1999; 66:224-30.
17. Nagafuchi S, Kashiwagi S, Okada K, et al. Reversal of non-responders and post-exposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA 1991; 265:2679-83.
18. Levitz RE, Cooper BW, Regan HC. Immunisation with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. Infection Control and Hospital Epidemiology 1995; 16:88-91.
19. Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, Looke DF, Whitby M. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infection Control and Hospital Epidemiology 2002; 23:87-90.
20. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355:561-5.
21. Alper CA, Kruskall MS, Marcus BD et al. Genetic prediction of non-response to hepatitis B vaccine. N Engl J Med 1989; 321:708-12.
22. Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infection Control and Hospital Epidemiology 2000; 21:264-9.